NEW HAVEN, Conn., June 17, 2014 – Melinta Therapeutics today announced that CEO Mary Szela will be presenting at the annual JMP Securities Healthcare Conference in New York, NY. Melinta’s presentation will take place on June 24, 2014 at 12:00 p.m. local time, and will include an update on delafloxacin, an investigational fluoroquinolone antibiotic with in vitro activity against both Gram positive and Gram negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Delafloxacin is currently being evaluated in three Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and uncomplicated gonorrhea, for which it has qualified infectious disease product (QIDP) status.
The JMP Securities annual healthcare conference is an institutional investor forum featuring publicly traded and privately held companies in the areas of biotechnology, specialty pharmaceuticals and medical devices. The conference is being held at The Westin New York Grand Central hotel in New York, NY from June 24-25. Attendance at this conference is by invitation only. For more information on the conference, please visit the JMP Securities website: www.jmpg.com.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is dedicated to the discovery, development and commercialization of groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI) and uncomplicated gonorrhea. Delafloxacin has been designated a qualified infectious disease product (QIDP) for ABSSSI, uncomplicated gonorrhea and community-acquired bacterial pneumonia by the U.S. Food and Drug Administration. A key initiative at Melinta is to develop, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the drug-resistant ESKAPE pathogens known to cause serious hospital infections. Melinta Therapeutics is privately held and backed by lead investor Vatera Healthcare Partners among other private investors. The company is headquartered in New Haven, CT with offices in Lincolnshire, IL.
For more information, visit www.melinta.com.